{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:04:38Z","timestamp":1790395478881,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006663.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,7,25]],"date-time":"2016-07-25T00:00:00Z","timestamp":1469404800000}}],"reference-count":109,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006663.pub4","type":"journal-article","created":{"date-parts":[[2016,7,25]],"date-time":"2016-07-25T19:51:20Z","timestamp":1469476280000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Enzyme replacement therapy for Anderson-Fabry disease"],"prefix":"10.1002","volume":"2017","author":[{"given":"Regina","family":"El Dib","sequence":"first","affiliation":[{"name":"Institute of Science and Technology, Unesp - Univ Estadual Paulista; Department of Biosciences and Oral Diagnosis; Botucatu Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda","family":"Gomaa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy,Tanta Chest Hospital; 3 Ahmed Kamal Street, Tanta Gharbia Egypt 112311"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00edssa Pierri","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Botucatu Medical School, UNESP - Univ Estadual Paulista; Avenida Camilo Mazoni, 1055 - F23 Jardim Paraiso Botucatu Sao Paulo Brazil 18610-285"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira E","family":"Camargo","sequence":"additional","affiliation":[{"name":"S\u00e3o Paulo State University - UNESP; Department of Biosciences and Oral Diagnosis; 777 Francisco Jose Longo S\u00e3o Jose dos Campos S\u00e3o Paulo S\u00e3o Paulo Brazil 12245-000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Bazan","sequence":"additional","affiliation":[{"name":"Botucatu Medical School, Universidade Estadual Paulista (UNESP); Department of Neurology; District of Rubiao Junior Botucatu, S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasqual","family":"Barretti","sequence":"additional","affiliation":[{"name":"Botucatu Medical School, UNESP - Univ Estadual Paulista; Clinical Medicine; Distrito de Rubi\u00e3o Junior, s\/n Botucatu S\u00e3o Paulo Brazil 18618-900"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fellype C","family":"Barreto","sequence":"additional","affiliation":[{"name":"Universidade Cat\u00f3lica do Paran\u00e1; School of Medicine Pontif\u00edcia; Rua Imaculada Concei\u00e7\u00e3o, 1155 Curitiba Paran\u00e1 Brazil 80215-901"},{"name":"Universidade Federal do Paran\u00e1 (UFPR); Department of Internal Medicine; Curitiba Paran\u00e1 Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,7,25]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD006663.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006663.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s10545-006-0361-5","article-title":"Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease","volume":"29","author":"Bierer","year":"2006","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0003|cit3","unstructured":"Bierer G Wilcox WR Balfe D Mosenifar Z Improvement in cardiopulmonary exercise testing during enzyme replacement therapy in Fabry disease [abstract] Proceedings of the American Thoracic Society International Conference;2005 May 20-25; San Diego, California 2005 A493"},{"issue":"8","key":"10.1002\/14651858.CD006663.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/GIM.0b013e318133fb1b","article-title":"The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease","volume":"9","author":"Clarke","year":"2007","journal-title":"Genetics in Medicine"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0005|cit5","first-page":"774","article-title":"Enzyme therapy for Fabry disease [abstract]","volume":"24 Suppl","author":"Desnick","year":"2001","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0006|cit6","first-page":"98","article-title":"Fabry disease enzyme therapy: phase 3 and extension results [abstract]","volume":"24 Suppl 1","author":"Desnick","year":"2001","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0008|cit8","first-page":"158","article-title":"Severe glomerulosclerosis and proteinuria may influence response to therapy in fabry disease [abstract]","volume":"26 Suppl 2","author":"Lee","year":"2003","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0009|cit9","first-page":"A22","article-title":"Aenzyme-supplementation therapy for Fabry disease: first possible treatment [abstract]","volume":"58","author":"Linthorst","year":"2001","journal-title":"The Netherlands Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006663.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.0022-202X.2004.22425.x","article-title":"Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies","volume":"122","author":"Thurberg","year":"2004","journal-title":"Journal of Investigative Dermatology"},{"issue":"19","key":"10.1002\/14651858.CD006663.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","article-title":"Cardiac Microvascular Pathology in Fabry Disease Evaluation of Endomyocardial Biopsies Before and After Enzyme Replacement Therapy","volume":"119","author":"Thurberg","year":"2009","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0012|cit12","first-page":"174","article-title":"Fabrazyme clears globotriaosylceramide from the skin of fabry patients [abstract]","volume":"26 Suppl 2","author":"Thurberg","year":"2003","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"6","key":"10.1002\/14651858.CD006663.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0014|cit14","first-page":"630","article-title":"Stabilization of renal function after enzyme replacement therapy in Fabry Disease [abstract]","volume":"18 Suppl 4","author":"Waldek","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"American Journal of Human Genetics"},{"issue":"8","key":"10.1002\/14651858.CD006663.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1023\/B:BOLI.0000009948.86528.72","article-title":"Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy","volume":"26","author":"Hajioff","year":"2003","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"443","key":"10.1002\/14651858.CD006663.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1651-2227.2003.tb00217.x","article-title":"Hearing improvement in patients with Fabry disease treated with agalsidase alfa","volume":"92","author":"Hajioff","year":"2003","journal-title":"Acta Paediatrica"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0018|cit18","first-page":"S26","article-title":"Hearing loss in Fabry's disease: the effect of alpha-galactosidase A replacement therapy [abstract]","volume":"54 Suppl 7","author":"Hajioff","year":"2003","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006663.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"issue":"3","key":"10.1002\/14651858.CD006663.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ymgme.2013.04.015","article-title":"A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease","volume":"109","author":"Hughes","year":"2013","journal-title":"Molecular Genetics and Metabolism"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1023\/A:1012451320105","article-title":"Enzyme replacement therapy in Fabry disease","volume":"24 Suppl 2","author":"Brady","year":"2001","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2377-2-4","article-title":"Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease","volume":"2","author":"Moore","year":"2002","journal-title":"BMC Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006663.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/hs0202.102601","article-title":"Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement","volume":"33","author":"Moore","year":"2002","journal-title":"Stroke"},{"issue":"13","key":"10.1002\/14651858.CD006663.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1161\/hc3801.096352","article-title":"Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy","volume":"104","author":"Moore","year":"2001","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mus.20550","article-title":"Enzyme replacement therapy and intraepidermal innervation density in Fabry disease","volume":"34","author":"Schiffmann","year":"2006","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1002\/14651858.CD006663.pub4-BIB0026|cit26","first-page":"775","article-title":"Clinical effect of enzyme replacement in Fabry disease [abstract]","volume":"24","author":"Schiffmann","year":"2001","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"21","key":"10.1002\/14651858.CD006663.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"499\u2013506","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry disease initiative","volume":"111","author":"Sirrs","year":"2014","journal-title":"Molecular Genetics and Metabolism"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0029|cit29","first-page":"S126, Abstract","article-title":"Agalsidase alfa and agalsidase beta have similar effects on fabry outcomes results from the Canadian fabry disease initiative [abstract]","volume":"33 Suppl 1","author":"Sirrs","year":"2010","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Vedder AC Linthorst GE Houge G Groener JE Ormel EE Bouma BJ Online CONSORT checklist S1 to 'Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg' [online] PLoS One 2007 e598","DOI":"10.1371\/journal.pone.0000598"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Vedder AC Linthorst GE Houge G Groener JE Ormel EE Bouma BJ Online supporting information to 'Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg' [online] PLoS One 2007 e598","DOI":"10.1371\/journal.pone.0000598"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0032|cit32","doi-asserted-by":"crossref","unstructured":"Vedder AC Linthorst GE Houge G Groener JE Ormel EE Bouma BJ Online trial treatment protocol S1 to 'Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg' [online] PLoS One 2007 e598","DOI":"10.1371\/journal.pone.0000598"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0033|cit33","doi-asserted-by":"crossref","unstructured":"Vedder AC Linthorst GE Houge G Groener JE Ormel EE Bouma BJ Online trial treatment protocol S2 to 'Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg' [online] PLoS One 2007 e598","DOI":"10.1371\/journal.pone.0000598"},{"issue":"7","key":"10.1002\/14651858.CD006663.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg","volume":"2","author":"Vedder","year":"2007","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0035|cit35","first-page":"62","article-title":"Enzyme replacement therapy in nine patients with Fabry disease","volume":"21 Suppl 11","author":"Alamartine","year":"2005","journal-title":"Medical Science"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ymgme.2005.04.009","article-title":"Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy","volume":"85","author":"Banikasemi","year":"2005","journal-title":"Molecular Genetics and Metabolism"},{"issue":"12","key":"10.1002\/14651858.CD006663.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease: overall effects of agalsidase alfa treatment","volume":"34","author":"Beck","year":"2004","journal-title":"European Journal of Clinical Investigation"},{"issue":"10","key":"10.1002\/14651858.CD006663.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"American Journal of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD006663.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease","volume":"69","author":"Breunig","year":"2006","journal-title":"Kidney international"},{"issue":"6","key":"10.1002\/14651858.CD006663.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1023\/B:BOLI.0000045841.27968.06","article-title":"Raised HDL cholesterol in Fabry disease: response to enzyme replacement therapy","volume":"27","author":"Cartwright","year":"2004","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"3","key":"10.1002\/14651858.CD006663.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/hrt.2004.054015","article-title":"Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A","volume":"92","author":"Elliott","year":"2006","journal-title":"Heart"},{"issue":"4","key":"10.1002\/14651858.CD006663.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10545-005-0575-y","article-title":"Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study","volume":"28","author":"Eto","year":"2005","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub4-BIB0043|cit43","first-page":"S154","article-title":"Evaluation of therapeutic efficacy in Fabry disease using Lyso-Gb3 as an indictor","volume":"37","author":"Tsuboi","year":"2014","journal-title":"Journal of inherited metabolic disease"},{"issue":"6","key":"10.1002\/14651858.CD006663.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1159\/000369293","article-title":"Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease","volume":"38","author":"Fellgiebel","year":"2014","journal-title":"Cerebrovascular Diseases"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0045|cit45","first-page":"S227","article-title":"Safety and tolerability of agalsidase alfa in patients with Fabry disease formerly treated with agalsidase beta","volume":"34 Suppl 3","author":"Fernhoff","year":"2011","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"5","key":"10.1002\/14651858.CD006663.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD006663.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/gim.2013.53","article-title":"Analysis of left ventricular mass in untreated men and in men treated with agalsidase-\u03b2: data from the Fabry Registry","volume":"15","author":"Germain","year":"2013","journal-title":"Genet Med"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0048|cit48","first-page":"116","article-title":"The clinical benefit of Fabrazyme treatment [abstract]","volume":"25 Suppl 1","author":"Guffon","year":"2002","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"2","key":"10.1002\/14651858.CD006663.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/B:BOLI.0000028726.11177.8b","article-title":"Clinical benefit in Fabry patients given enzyme replacement therapy - a case series","volume":"27","author":"Guffon","year":"2004","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"9","key":"10.1002\/14651858.CD006663.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1365-2362.2006.01701.x","article-title":"Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey","volume":"36","author":"Hajioff","year":"2006","journal-title":"European Journal of Clinical Investigation"},{"issue":"7","key":"10.1002\/14651858.CD006663.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","article-title":"Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy","volume":"62","author":"Hilz","year":"2004","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006663.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10545-006-0339-3","article-title":"Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease","volume":"29","author":"Jardim","year":"2006","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"3B","key":"10.1002\/14651858.CD006663.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1590\/S0004-282X2006000500002","article-title":"White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up","volume":"64","author":"Jardim","year":"2006","journal-title":"Arquivos de Neuro-Psiquiatria"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10545-006-0221-3","article-title":"The effect os 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease","volume":"29","author":"Kalliokoshi","year":"2006","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"2","key":"10.1002\/14651858.CD006663.pub4-BIB0055|cit55","first-page":"R5","article-title":"Influence of enzyme replacement therapy (ERT) on Anderson Fabry disease associated hypertrophic infiltrative cardiomyopathy (HIC)","volume":"161","author":"Kampmann","year":"2002","journal-title":"European Journal of Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD006663.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/jcph.262","article-title":"First-in-human study with new recombinant agalsidase beta (ISU303) in healthy subjects","volume":"54","author":"Kim","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0057|cit57","first-page":"166","article-title":"Safety of enzyme replacement therapy among 20 Japanese patients with classical type of Fabry disease [abstract]","volume":"28 Suppl 1","author":"Kobayashi","year":"2005","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"3","key":"10.1002\/14651858.CD006663.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1523-1755.2004.00883.x","article-title":"Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease","volume":"66","author":"Kosch","year":"2004","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006663.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ndt\/gfi221","article-title":"Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands","volume":"21","author":"Linthorst","year":"2006","journal-title":"Nephrology, Dialysis, Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006663.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1523-1755.2004.00514.x","article-title":"Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study","volume":"65","author":"Mignani","year":"2004","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0062|cit62","first-page":"163","article-title":"Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease","volume":"163","author":"Mills","year":"2004","journal-title":"European Journal of Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2005.03.016","article-title":"Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement","volume":"46","author":"Pisani","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1651-2227.2007.00029.x","article-title":"Enzyme replacement therapy with agalsidase alfa in children with Fabry disease","volume":"96","author":"Ramaswami","year":"2007","journal-title":"Acta Paediatrica"},{"issue":"3","key":"10.1002\/14651858.CD006663.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","article-title":"Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease","volume":"118","author":"Ries","year":"2006","journal-title":"Pediatrics"},{"issue":"10","key":"10.1002\/14651858.CD006663.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1002\/14651858.CD006663.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","article-title":"Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease","volume":"28","author":"Schiffmann","year":"2003","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD006663.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrology, Dialysis, Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD006663.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/gim.2013.56","article-title":"Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa","volume":"15","author":"Schiffmann","year":"2013","journal-title":"Genet Med"},{"issue":"9","key":"10.1002\/14651858.CD006663.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13023-014-0169-6","article-title":"Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study","volume":"26","author":"Schiffmann","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0071|cit71","first-page":"S186, Abstract","article-title":"Rate of decline of GFR in patients with fabry disease (FD): prospective natural history data from the Canadian fabry disease initiative (CFDI) [abstract]","volume":"34 Suppl 3","author":"Sirrs","year":"2011","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-0004.2004.00284.x","article-title":"Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease","volume":"66","author":"Spinelli","year":"2004","journal-title":"Clinical Genetics"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0073|cit73","first-page":"S154, Abstract","article-title":"Evaluation of the efficacy of enzyme replacement therapy for cardiac hypertrophy in Fabry disease [abstract]","volume":"37 Suppl 1","author":"Tsuboi","year":"2014","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0074|cit74","first-page":"S154, Abstract","article-title":"Evaluation of therapeutic efficacy in Fabry disease using Lyso-Gb3 as an indictor [abstract]","volume":"37 Suppl 1","author":"Tsuboi","year":"2014","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"T\u00f8ndel","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"1-2","key":"10.1002\/14651858.CD006663.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cccn.2005.04.036","article-title":"Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments","volume":"360","author":"Utsumi","year":"2005","journal-title":"Clinica Chimica Acta"},{"issue":"11","key":"10.1002\/14651858.CD006663.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD006663.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1681\/ASN.2013060585","article-title":"Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch","volume":"25","author":"Weidemann","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"S3\u2013S47","DOI":"10.1016\/j.ymgme.2010.11.168","article-title":"Agalsidase alfa and agalsidase beta have similar effects on outcomes in Fabry disease \u2013 results from the Canadian Fabry disease initiative","volume":"102","author":"West","year":"2011","journal-title":"Molecular Genetics and Metabolism"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0080|cit80","first-page":"S161, Abstract","article-title":"Migalastat reduces plasma globotriaosylsphingosine (lyso-Gb3) in Fabry patients: results from the FACETS phase 3 study [abstract]","volume":"37 Suppl 1","author":"Benjamin","year":"2014","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD006663.pub4-BIB0081|cit81","first-page":"Abstract no: O-","article-title":"Subjects treated with migalastat continue to demonstrate stable renal function and reduced left ventricular mass index over 3 years in a long-term extension study of Fabry disease [abstract]","volume":"38","author":"Germain","year":"2015","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006663.pub4-BIB0082|cit82","first-page":"S95: Abstract P","article-title":"Migalastat HCl, an investigational pharmacological chaperone therapy: screen results from FACETS, a phase 3 study in male and female fabry patients [abstract]","volume":"35","author":"Nicholls","year":"2012","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0083|cit83","first-page":"S158, Abstract","article-title":"Development of a next-generation ERT, ATB100C, for fabry disease [abstract]","volume":"37 Suppl 1","author":"Hughes","year":"2014","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0084|cit84","unstructured":"NCT00701415 A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-na\u00efve, Male Pediatric Patients Without Severe Symptoms (FIELD) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00701415"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006663.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"e0124987","DOI":"10.1371\/journal.pone.0124987","article-title":"Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial","volume":"10","author":"Wijburg","year":"2015","journal-title":"PloS One"},{"issue":"8","key":"10.1002\/14651858.CD006663.pub4-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13023-015-0296-8","article-title":"Quality of life in patients with Fabry disease: a systematic review of the literature","volume":"10","author":"Arends","year":"2015","journal-title":"Orphanet Journal of Rare Diseses"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"995\u20138","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \u201cquality of evidence\u201d and why is it important to clinicians","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7414","key":"10.1002\/14651858.CD006663.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0092|cit92","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated March 2011) The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2008.10.013","article-title":"Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?","volume":"96","author":"Hollak","year":"2009","journal-title":"Molecular Genetics and Metabolism"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1740774508100984","article-title":"Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials","volume":"6","author":"Jones","year":"2009","journal-title":"Clinical trials"},{"issue":"3","key":"10.1002\/14651858.CD006663.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub4-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"issue":"5","key":"10.1002\/14651858.CD006663.pub4-BIB0097|cit97","first-page":"gin\/30.5.5","article-title":"Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature","volume":"30","author":"Riccio","year":"2013","journal-title":"G Ital Nefrol"},{"issue":"10","key":"10.1002\/14651858.CD006663.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1177\/0091270007305299","article-title":"Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents","volume":"47","author":"Ries","year":"2007","journal-title":"Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006663.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/heart.84.4.390","article-title":"A comparison of four quality of life instruments in cardiac patients: SF-36, QLI, QLMI, and SEIQoL","volume":"84","author":"Smith","year":"2000","journal-title":"Heart"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"American Journal of Human Genetics"},{"key":"10.1002\/14651858.CD006663.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/9780470693926.ch11","article-title":"Investigating and dealing with publication and other biases","volume-title":"Systematic Reviews in Health Care","author":"Sterne","year":"2001"},{"issue":"5","key":"10.1002\/14651858.CD006663.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0895-4356(99)00204-8","article-title":"Misleading funnel plot for detection of bias in meta-analysis","volume":"53","author":"Tang","year":"2000","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD006663.pub4-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0895-4356(99)00161-4","article-title":"Publication bias in meta-analysis: its causes and consequences","volume":"53","author":"Thornton","year":"2000","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD006663.pub4-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genetics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006663.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Molecular Genetics and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD006663.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"Wraith","year":"2008","journal-title":"Journal of Pediatrics"},{"issue":"447","key":"10.1002\/14651858.CD006663.pub4-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1651-2227.2005.tb02112.x","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatr Suppl"},{"issue":"5","key":"10.1002\/14651858.CD006663.pub4-BIB0108|cit108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006663.pub2","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","author":"Dib","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006663.pub4-BIB0109|cit109","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006663.pub3","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","author":"Dib","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006663.pub4\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T08:10:59Z","timestamp":1710835859000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006663.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,7,25]]},"references-count":109,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006663.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,25]]}}}